AK-1286
/ Shanghai YingLi Pharma, Azkarra Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 16, 2025
AK-1286-001: A Study of AK-1286 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1